Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Galderma Group AG today and set a price target of CHF112.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benjamin Jackson CFA has given his Buy rating due to a combination of factors including Galderma Group AG’s impressive financial performance in the first half of the year. The company’s sales exceeded expectations by 3%, driven by strong performance in its Nemluvio product line and Injectable Aesthetics, which saw a 9.8% increase in sales. This growth suggests better-than-expected pricing realization in the US and successful launches in Germany.
Furthermore, the company’s 2025 sales outlook has been revised upwards to 12%-14%, indicating a positive future trajectory despite some anticipated challenges in the second half of the year. The core EBITDA margin target remains consistent, hinting at potential profit increases. The Therapeutic Dermatology segment, particularly Nemluvio, outperformed expectations, with sales significantly surpassing consensus figures. Additionally, the Injectable Aesthetics segment continues to gain market share, driven by double-digit growth in both the US and international markets.
In another report released on July 21, Barclays also maintained a Buy rating on the stock with a CHF133.00 price target.